GlaxoSmithKline announced Financial Results for the period ended June 30, 2017.
The company’s Sales for the period increased by 25 percent in the outgoing year, whereas the Total Profit after Taxation for the Period increased by 33 percent.
The board has recommended no Cash Dividend, any bonus or right shares.
Comparison of Key Financials
Unconsolidated Profit and Loss Account – For the Six Months Ended
Key Financials
Jan – June, 2017
Jan – Jun, 2016
% Change
Amounts in PKR ‘000
Sales
16,208,185
12,916,465
25%
Cost of Sales
11,824,067
9,510,709
24%
Gross Profit
4,384,118
3,405,756
29%
Selling, Marketing and Dist: Expenses
1,478,058
1,355,368
9%
Admin: Expenses
482,952
490,813
-2%
Other Operating Expenses
222,013
137,921
61%
Other Income
294,599
196,516
50%
Profit from Operations
2,495,694
1,618,170
54%
Finance Cost
9,761
8,598
14%
Profit before Taxation
2,485,933
1,609,752
54%
Taxation
1,027,937
675,049
52%
Profit after Taxation from Continued Operations
1,457,996
934,523
56%
(Loss)/Profit after Taxation from dis-continued Operations
(31,721)
138,816
-123%
Total Profit after Operations
1,426,275
1,073,339
33%
EPS – Continued Operations
4.58
2.93
56%
EPS – Discontinued Operations
(0.10)
0.44
-123%
EPS
4.48
3.37
33%
Company release on Earnings Report can be accessed here.